The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). (Q44165791)

30 November 2017

title

The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). (English)

1 reference

30 November 2017

1 reference

1 reference

9

1 reference

30 November 2017

5

Smaill JB

1 reference

30 November 2017

Singleton DC

1

1 reference

30 November 2017

Li D

2

1 reference

30 November 2017

Bai SY

3

1 reference

30 November 2017

Syddall SP

4

1 reference

30 November 2017

Shen Y

6

1 reference

30 November 2017

Denny WA

7

1 reference

30 November 2017

Wilson WR

8

1 reference

30 November 2017

publication date

2 November 2007

1 reference

30 November 2017

1 reference

30 November 2017

volume

14

1 reference

30 November 2017

issue

12

1 reference

30 November 2017

page(s)

953-967

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7701088

30 November 2017

exact match

0 references

cites work

Cytolytic viruses as potential anti-cancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Oncolytic biotherapy: a novel therapeutic plafform

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

1 reference

7 January 2021

Selectively replicating viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Adenoviral vectors: systemic delivery and tumor targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Replicative oncolytic adenoviruses in multimodal cancer regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Update on adenovirus and its vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Production of adenovirus vector for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Modelling the molecular circuitry of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Regulation of endogenous E2F1 stability by the retinoblastoma family proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

1 reference

7 January 2021

The INK4a/ARF network in tumour suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Tumor-specific intravenous gene delivery using oncolytic adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Biosafety and product release testing issues relevant to replication-competent oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Prodrug strategies in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Prodrug activation enzymes in cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Nitroreductase-based GDEPT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Aerobic 2- and 4-nitroreduction of CB 1954 by human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Nitroaryl Phosphoramides as Novel Prodrugs for E. coli Nitroreductase Activation in Enzyme Prodrug Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Quantitation of protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

CB 1954 revisited. II. Toxicity and antitumour activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Effect of hypoxia on Ad5 infection, transgene expression and replication.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Exploiting tumour hypoxia in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701088

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7701088

1 reference

30 November 2017

1 reference